Literature DB >> 7990977

Effects of neuropeptide Y and vasoactive intestinal peptide on human venous smooth muscle in vivo.

M Wolzt1, W Gerschlager, B Zweytick, B Jilma, H Riemer, K Sertl, H G Eichler.   

Abstract

The direct and noradrenaline-modulating effects of neuropeptide Y (NPY) and vasoactive intestinal peptide (VIP) on venous smooth muscle were studied in healthy volunteers employing the dorsal hand vein compliance technique. Local infusions of NPY had no measurable effect on venous tone, but coinfusion of a constant high dose of NPY (242 pmol/min) with noradrenaline caused a 2.9-fold increase in the mean ED50 for noradrenaline. The dilating effect of VIP on preconstricted hand veins was weak, maximal venodilation could not be achieved, because systemic side effects occurred at submaximally venodilating doses. Coinfusion of noradrenaline with a weakly venodilating, constant dose of VIP (93.2 pmol/min) caused a 0.5-fold decrease in the sensitivity for noradrenaline. Although functional interactions between NPY or VIP and noradrenaline could be demonstrated, the dosages of the peptides required were high. Thus our results indicate that neither NPY nor VIP exert a major direct or noradrenaline-modulating effect on human veins.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7990977     DOI: 10.1007/BF00241096

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  39 in total

1.  Genetic aspects of variability in superficial vein responsiveness to norepinephrine.

Authors:  A Luthra; K R Borkowski; S G Carruthers
Journal:  Clin Pharmacol Ther       Date:  1991-04       Impact factor: 6.875

Review 2.  Neuropeptides in the airways: a review.

Authors:  R Uddman; F Sundler
Journal:  Am Rev Respir Dis       Date:  1987-12

3.  Vasodepressor neurons in medulla alter cardiac contractility and cardiac output.

Authors:  G Drolet; J Chalmers; W Blessing
Journal:  Hypertension       Date:  1993-02       Impact factor: 10.190

4.  [Leu31, Pro34]neuropeptide Y: a specific Y1 receptor agonist.

Authors:  J Fuhlendorff; U Gether; L Aakerlund; N Langeland-Johansen; H Thøgersen; S G Melberg; U B Olsen; O Thastrup; T W Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

5.  D-myo-inositol-1,2,6-triphosphate (PP56) antagonizes nonadrenergic sympathetic vasoconstriction: possible involvement of neuropeptide Y.

Authors:  J H Schwieler; P Hjemdahl
Journal:  J Cardiovasc Pharmacol       Date:  1993-03       Impact factor: 3.105

6.  Effects of clonidine on plasma catecholamines and neuropeptide Y in hypertensive patients at rest and during stress.

Authors:  L Puybasset; P Lacolley; S Laurent; F Mignon; E Billaud; J L Cuche; E Comoy; M Safar
Journal:  J Cardiovasc Pharmacol       Date:  1993-06       Impact factor: 3.105

7.  Neuropeptide Y-like immunoreactivity and hypertension.

Authors:  D Erlinge; R Ekman; T Thulin; L Edvinsson
Journal:  J Hypertens       Date:  1992-10       Impact factor: 4.844

8.  Characterization of vascular postsynaptic neuropeptide Y receptor function and regulation. 1. NPY-induced constriction in isolated rat femoral artery rings is mediated by both Y1 and Y2 receptors: evidence from benextramine protection studies.

Authors:  R E Tessel; D W Miller; G A Misse; X Dong; M B Doughty
Journal:  J Pharmacol Exp Ther       Date:  1993-04       Impact factor: 4.030

9.  Vasodilatation by calcitonin gene-related peptide and by substance P: a comparison of their effects on resistance and capacitance vessels of human forearms.

Authors:  J R McEwan; N Benjamin; S Larkin; R W Fuller; C T Dollery; I MacIntyre
Journal:  Circulation       Date:  1988-05       Impact factor: 29.690

10.  Interaction of neuropeptide Y and the sympathetic nervous system in vascular control in man.

Authors:  J Clarke; N Benjamin; S Larkin; D Webb; A Maseri; G Davies
Journal:  Circulation       Date:  1991-03       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.